2. JAK/STAT Signaling Protein Tyrosine Kinase/RTK
  3. EGFR
  4. Pertuzumab

Pertuzumab  (Synonyms: 帕妥株单抗)

目录号: HY-P9912 纯度: 99.80%
COA

摩尔计算器

Pertuzumab 是一种人源化 IgG1 单克隆抗体，是一种HER2二聚抑制剂。可用于转移性HER2 阳性乳腺癌的研究。

MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

CAS No. : 380610-27-5

1.  客户无需承担相应的运输费用。

2.  同一机构（单位）同一产品试用装仅限申领一次，同一机构（单位）一年内

     可免费申领三个不同产品的试用装。

3.  试用装只面向终端客户。

规格 价格 是否有货 数量
1 mg ￥1900
In-stock
5 mg ￥4200
In-stock
10 mg ￥6500
In-stock
50 mg   询价  
100 mg   询价  

* Please select Quantity before adding items.

Customer Review

Pertuzumab 相关抗体

Top Publications Citing Use of Products

查看 EGFR 亚型特异性产品:

查看所有亚型
EGFR/ErbB1/HER1 ErbB2/HER2 ErbB3/HER3 ErbB4/HER4

  • 生物活性

  • 实验参考方法

  • 纯度 & 产品资料

  • 参考文献

生物活性

Pertuzumab, a humanized IgG1 monoclonal antibody, is a HER2 dimerization inhibitor for the treatment of metastatic HER2-positive breast cancer.

IC50 & Target

HER2

 

体外研究
(In Vitro)

Trastuzumab 和 Pertuzumab 在抑制 BT474 乳腺癌细胞存活方面表现出高度协同作用。两者组合在个体药物未改变细胞存活率的剂量下导致多达 60% 的细胞丧失；组合显著降低增殖 (S 期) 细胞比例超过两倍；抑制细胞增殖和存活的效果优于单独使用任一药物[1]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Pertuzumab 相关抗体:
体内研究
(In Vivo)

在 Calu-3 NSCLC 异种移植中，使用Pertuzumab 或曲妥珠单抗单药治疗能够显著抑制肿瘤生长，治疗对照比 (TCR) 分别为 0.23 和 0.27。曲妥珠单抗和Pertuzumab 的组合与单药治疗相比，可产生显著增强的抗肿瘤活性(TCR 0.05，导致肿瘤消退，并且在 10 只动物中有 3 只肿瘤完全缓解)。使用曲妥珠单抗或Pertuzumab 治疗 KPL-4 乳腺癌异种移植可抑制肿瘤生长，TCR 分别为 0.67 和 0.65。在曲妥珠单抗治疗进展后，Pertuzumab 仍保持抗肿瘤活性[2]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Clinical Trial
CAS 号
性状

液体

颜色

Colorless to light yellow

中文名称

帕妥株单抗
储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.
Format
  • Human IgG1 kappa
Biological Activity
  • Pertuzumab has a significant ADCC effect on SK-BR-3 cells in a dose-dependent manner.The EC50 for this effect is 61.54 and 74.56 ng/mL.
纯度 & 产品资料

纯度: 99.80%

COA (264 KB)

抗体抑制剂使用指南 (1152 KB)
参考文献
Cell Assay
[1]

BT474 cells are seeded at 5×104 cells/well in 12-well dishes. After 24 h, cells are treated in triplicate with 2-fold serial dilutions of trastuzumab, Pertuzumab, or both drugs simultaneously at a fixed 1:1 ratio at low doses ranging from 0.9 ng/mL to 10 ng/mL. After 5 days, cells are trypsinized and counted by trypan blue exclusion. Growth inhibition is calculated as the percentage of viable cells compared with untreated cultures[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Animal Administration
[2]

Mice: Calu-3 or KPL-4 tumors (100 mm3) are treated with trastuzumab (30 mg/kg loading dose, then 15 mg/kg weekly), Pertuzumab (30 mg/kg loading dose, then 15 mg/kg weekly), or both, administered i.p. for the duration of the study. Tumor volumes and body weights are measured twice weekly. For the acute study, advanced Calu-3 tumors of 400 mm3 are treated once with trastuzumab and/or Pertuzumab at a dose of 30 mg/kg. Samples are harvested 7 d later for immunohistochemistry (IHC) and Western blot analysis[2].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.
参考文献

Pertuzumab 相关分类

  • 摩尔计算器

  • 稀释计算器

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

质量   浓度   体积   分子量 *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

浓度 (start) × 体积 (start) = 浓度 (final) × 体积 (final)
× = ×
C1   V1   C2   V2
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Pertuzumab380610-27-5帕妥株单抗EGFREpidermal growth factor receptorErbB-1HER1Inhibitorinhibitorinhibit

您最近查看的产品:

Your information is safe with us. * Required Fields.

   产品名称：

  

* 需求量：

* 客户姓名：

 

* Email：

* 电话：

 

* 公司或机构名称：

   留言给我们：

Bulk Inquiry

Inquiry Information

产品名称：
Pertuzumab
目录号：
HY-P9912
需求量：

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

   产品名称：

  

* Lot #：

* 客户姓名：

 

* Email：

   电话：

 

* 部门：

* 公司或机构名称：

 

   留言给我们：

Request for HNMR Report

We have received your request and will respond to you as soon as possible.

嗨！很高兴为您提供帮助！

尊敬的 MCE 客户您好，
请您选择所在区域，我们将转接对应客服为您服务！

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

热 A B C F G H J L N Q S T X Y Z